Literature DB >> 7943173

Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68.

N P Sunil-Chandra1, J Arno, J Fazakerley, A A Nash.   

Abstract

Murine gammaherpesvirus is a natural pathogen of wild rodents. In the laboratory it establishes an infection of epithelial cells and persists in B lymphocytes in a latent form. Inbred mice chronically infected with the virus develop a lymphoproliferative disease (LPD) similar to that seen in patients infected with Epstein-Barr virus. The frequency of LPD over a period of 3 years was 9% of all infected animals, with 50% of these displaying high grade lymphomas. The incidence of LPD was greatly increased when infected mice were treated with cyclosporin A. The majority of mice used in the experiments were BALB/c, although lymphomas were detected in mice on other genetic backgrounds, ie, CBA and B10Br. Lymphomas were associated with both lymphoid and nonlymphoid tissues (liver, lung, and kidney). In all cases of lymphomas studied thus far, there was a mixed B cell (B220+ve) and T cell (CD3+ve) phenotype. The B cells were light chain restricted, indicative of a clonal origin. Variable numbers of virus genome-positive cells were detected by in situ hybridization in and around the lymphomas. In contrast, no lytic antigen-positive cells were detected, indicating that genome-positive cells were either latently infected or undergoing an abortive infection. These observations suggest that murine gammaherpesvirus-infected mice may be an important model to study the pathogenesis of LPD associated with other gammaherpesviruses, such as Epstein-Barr virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943173      PMCID: PMC1887324     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

2.  Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization.

Authors:  J G Howe; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Different Epstein-Barr virus expression in lymphomas from immunocompromised and immunocompetent patients.

Authors:  B Borisch-Chappuis; C Nezelof; H Müller; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

4.  In situ demonstration of Epstein-Barr viral genomes in viral-associated B cell lymphoproliferations.

Authors:  L M Weiss; L A Movahed
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

5.  Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins.

Authors:  L S Young; S Finerty; L Brooks; F Scullion; A B Rickinson; A J Morgan
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice.

Authors:  M J Cannon; P Pisa; R I Fox; N R Cooper
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

7.  Interactions of murine gammaherpesvirus 68 with B and T cell lines.

Authors:  N P Sunil-Chandra; S Efstathiou; A A Nash
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

8.  Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus.

Authors:  T Shope; D Dechairo; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

9.  Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus.

Authors:  D W Hanto; G Frizzera; D T Purtilo; K Sakamoto; J L Sullivan; A K Saemundsen; G Klein; R L Simmons; J S Najarian
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

10.  Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients.

Authors:  G Frizzera; D W Hanto; K J Gajl-Peczalska; J Rosai; R W McKenna; R K Sibley; K P Holahan; L L Lindquist
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

View more
  81 in total

1.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells.

Authors:  S M Kaech; R Ahmed
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

2.  Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells.

Authors:  K E Weck; S S Kim; I V Virgin HW; S H Speck
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Murine gammaherpesvirus 68 cyclin D homologue is required for efficient reactivation from latency.

Authors:  A T Hoge; S B Hendrickson; W H Burns
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  Gammaherpesvirus lytic gene expression as characterized by DNA array.

Authors:  Joo Wook Ahn; Kenneth L Powell; Paul Kellam; Dagmar G Alber
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice.

Authors:  Shivaprakash Gangappa; Sharookh B Kapadia; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Complete sequence and genomic analysis of murine gammaherpesvirus 68.

Authors:  H W Virgin; P Latreille; P Wamsley; K Hallsworth; K E Weck; A J Dal Canto; S H Speck
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

7.  Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.

Authors:  James Scott McClellan; Scott A Tibbetts; Shivaprakash Gangappa; Kelly A Brett; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection.

Authors:  Rebecca L Sparks-Thissen; Douglas C Braaten; Scott Kreher; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.

Authors:  Tammy M Rickabaugh; Helen J Brown; DeeAnn Martinez-Guzman; Ting-Ting Wu; Leming Tong; Fuqu Yu; Steven Cole; Ren Sun
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Expression in a recombinant murid herpesvirus 4 reveals the in vivo transforming potential of the K1 open reading frame of Kaposi's sarcoma-associated herpesvirus.

Authors:  Jill Douglas; Bernadette Dutia; Susan Rhind; James P Stewart; Simon J Talbot
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.